Aster DM Quality Care Q1 FY27: The first quarter as a merged platform

Aster DM Quality Care Limited entered FY27 as a newly formed hospital chain, with the merger becoming effective on July 1, 2026. The Q1 FY27 results discussed in the investor presentation and earnings call were therefore presented on a proforma basis for the combined entity.

On that proforma basis, the merged platform reported revenue from operations of INR 2,597 crore in Q1 FY27, up 20 percent year-on-year, and operating EBITDA of INR 576 crore, up 30 percent. Operating EBITDA margin expanded by 170 basis points to 22.2 percent. Management framed this quarter as a volume-led growth story supported by a higher complexity case mix, with early signs of operating leverage.

At an operating level, total patient volume for the combined entity rose to 2.01 million, up 13 percent year-on-year. Occupancy improved to 64 percent, and ALOS was 3.40 days. The company also highlighted ARPP improving 10 percent year-on-year to INR 1,36,802, driven by growth in high-end tertiary procedures, including robotics, transplants and joint replacements.

What the merger changes and what it does not

Management was explicit that the operational transition on July 1 was executed with zero service disruption. The company highlighted cultural integration activities across 41 plus sites and leadership engagement across thousands of doctors and senior executives.

But it also drew an important line: the Q1 FY27 performance was not attributed to merger synergies. Management stated that synergies had not yet played out and that the quarter reflected the independent execution of the two platforms. This distinction matters because it frames the synergy program as incremental, not embedded in the reported results.

A key corporate announcement also highlighted a structural shift in shareholding due to the merger. Under the amalgamation scheme, Aster DM Quality Care allotted shares to eligible QCIL shareholders in a ratio of 977 shares for every 1,000 QCIL shares, resulting in promoter and promoter group dilution to 24.01 percent from 40.39 percent.

Aster versus Quality Care: proforma split and operating momentum

For Q1 FY27, the company disclosed proforma revenue and operating EBITDA at the platform level.

On the Aster platform, revenue rose 22 percent year-on-year to INR 1,311 crore. Operating EBITDA increased 29 percent to INR 277 crore, with margin improving to 21.1 percent. Normalised PAT (post NCI) grew 39 percent to INR 125 crore, excluding merger-related exceptional expenses of INR 114.4 crore.

Aster also provided a segment mix for its business. Hospitals and clinics remained the core at 95 percent of revenue, while pharmacy was 2 percent and labs were 3 percent.

On the Quality Care platform, revenue grew 19 percent year-on-year to INR 1,287 crore. Operating EBITDA increased 32 percent to INR 299 crore, with margin expanding by 216 basis points to 23.2 percent. Occupancy improved to 65.4 percent and ARPP improved to about INR 1,44,064.

Patient mix, clinical complexity and Medical Value Travel

The investor presentation included a payer mix and specialty mix for the merged entity’s hospitals and clinics. Walk-in remained the largest at 53 percent, while corporate and insurance was 34 percent, government schemes 9 percent, and Medical Value Travel 4 percent.

Medical Value Travel emerged as a focus narrative. The deck reported MVT growth of 62 percent supported by new geographies. In the call, management acknowledged that MVT contribution remains low compared with peers, but indicated an intention to grow it faster than the core business. Varun Khanna stated that the company expects MVT growth in excess of 50 percent and over time aims to move MVT contribution from low single digits to mid-single digits and eventually to double digits.

On clinical momentum, management repeatedly emphasised a push toward high-acuity services. The deck highlighted robotics, transplants, cardiac sciences, oncology, neurosciences and orthopaedics as key growth drivers. It also reported clinical infrastructure at a combined level including cathlabs, LINACs, MRI machines and robots, and cited TTM procedure volumes such as cardiac procedures, neuro procedures, robotic surgeries, joint procedures and transplants.

Margin trajectory and synergy roadmap

A key forward-looking element was the medium-term margin target. During Q&A, management reiterated that it does not provide quarter-on-quarter or annual guidance, but reaffirmed a broad target of reaching 24 to 25 percent EBITDA margin within two to three years post-merger. In response to a specific question, the CFO indicated that the target could be reached between FY28 and FY29.

The company also reiterated the synergy opportunity. The presentation states the merged entity is well positioned to deliver a 10 to 15 percent EBITDA uplift, expressed as a percentage of FY24 proforma EBITDA. In the call, management reiterated this target and framed the near-term synergy quantum as approximately INR 150 to 200 crore.

The synergy program was structured around a set of initiatives that include material cost optimisation, indirect cost optimisation, KPI and reporting standardisation, IT integration, capex efficiencies, renewable energy savings, and talent sharing.

Expansion plans: bed additions and near-term project timelines

Aster DM Quality Care disclosed a multi-year expansion plan to add 4,179 beds, taking total capacity to 15,077 beds. The plan is presented year-wise:

• FY27: 634 beds (180 brownfield, 454 greenfield)
• FY28: 1,190 beds (430 brownfield, 760 greenfield)
• FY29: 1,555 beds (1,360 brownfield, 195 greenfield)
• FY30 and beyond: 800 beds (250 brownfield, 550 greenfield)

The company highlighted that 53 percent of planned additions are in existing facilities. Management framed this as a way to reduce gestation time and execution risk.

On the call, the CFO shared specific commissioning timelines for key Aster projects: Trivandrum targeted for H2 FY27 (around January 2027), Hyderabad targeted around April 2027, and Sarjapur Phase I targeted for H2 FY28.

Separately, the deck highlighted a recently commissioned project: the 159-bed Women and Children block at Aster Whitefield, inaugurated in April 2026, with an investment of INR 96 crore.

What to track from here

The proforma numbers show that the combined entity entered FY27 with healthy growth and improving margins. The company’s operating narrative is built around rising occupancy, a more complex case mix, and the scaling of clinical programs.

However, management has also flagged that the proforma figures are subject to finalisation and audit adjustments, and that reported numbers could differ based on harmonisation of accounting policies.

For investors, the next few quarters are likely to be evaluated on two execution tests. First, whether synergies translate into measurable savings and margin expansion without service disruption. Second, whether the expansion pipeline, especially brownfield additions, delivers faster ramp-up and supports return metrics.

The company is positioning itself as a single platform with 39 hospitals and a clear ambition to lift margins toward 24 to 25 percent over the next two to three years. If the integration remains stable and the synergy wheel moves from intent to delivery, Q1 FY27 could be remembered as the quarter that established the baseline rather than the peak.